382 filings
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
425
SPRC
SciSparc Ltd
2 May 24
Business combination disclosure
4:46pm
6-K
SPRC
SciSparc Ltd
2 May 24
Consolidated Financial Statements as for Consolidated Financial Statements as for To the shareholders of
4:02pm
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
6-K
sznq9f9grh7bitgkx
11 Apr 24
Agreement and Plan of Merger
4:05pm
S-8
xwuivzxa29klull
1 Apr 24
Registration of securities for employees
5:11pm
6-K
spmgz
27 Mar 24
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
9:18am
6-K
2b6q fil69mtqlagm6ba
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
6-K
eo09go
13 Mar 24
Report of Foreign Private Issuer
9:06am
6-K
kwb1jrzjew6 barsqy
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
EFFECT
sny1f3zieimz3b9tk
7 Mar 24
Notice of effectiveness
12:15am
6-K
4phs4ks8e7
29 Feb 24
Report of Foreign Private Issuer
9:07am
F-1
74hmck0ubksyd58p
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
trygf
27 Feb 24
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
8:35am
6-K
xg854
20 Feb 24
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
4:27pm
6-K
dxh86z
12 Feb 24
Report of Foreign Private Issuer
4:27pm
6-K
6uw xlt19g04
29 Jan 24
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
4:00pm
6-K
7dzra
25 Jan 24
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
9:05am